Abeona Therapeutics Inc. (NASDAQ:ABEO) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $25.43.

ABEO has been the topic of several research analyst reports. Zacks Investment Research cut shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. BidaskClub cut shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada began coverage on shares of Abeona Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price target on the stock. Cantor Fitzgerald restated a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, October 6th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Friday, September 8th.

Institutional investors have recently bought and sold shares of the company. State of Wisconsin Investment Board purchased a new position in shares of Abeona Therapeutics during the 2nd quarter valued at $122,000. Rhumbline Advisers acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at $190,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at $264,000. Bank of New York Mellon Corp lifted its stake in shares of Abeona Therapeutics by 125.8% in the 1st quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 23,358 shares during the last quarter. Finally, California State Teachers Retirement System acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at $275,000. Institutional investors and hedge funds own 33.60% of the company’s stock.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million.

COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics Inc. (ABEO) Receives Average Recommendation of “Buy” from Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/02/abeona-therapeutics-inc-abeo-receives-average-recommendation-of-buy-from-analysts.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.